(Chicago, IL and Daejeon, South Korea) Korean research Institute of Bioscience and Biotechnology (KRIBB), a world leader in the integrated biotechnology and bioinformatics has licensed the ERGO™ bioinformatics software developed and maintained by Integrated Genomics. KRIBB will utilize the ERGO™ genome analysis tools for gene annotation, metabolic reconstruction and enzyme data-mining as well as for comparative genomics purposes.
"The ERGO platform gives us a valuable and comprehensive resource for our genomics studies and provides a powerful data-mining environment for our systems biology scientists" said Dr Dooil Kim, Professor at the System Microbiology Research Center Division at KRIBB.
Optimized for analysis of microorganisms, ERGO™ integrates biological data from genomics, biochemistry, gene expression studies, genetics and literature. Reaching beyond conventional systems for functional analysis by DNA sequence alone, Integrated Genomics' platform combines pattern-based analyses with a repertoire of comparative genomics tools for gene visualization in the contexts of regulation, expression data, phylogeny, chromosomal neighborhoods and gene fusions. ERGO? contains more than 1236 genomes at various stages of completion, as well as the largest available collection of networked cellular pathways.
About Integrated Genomics
Integrated Genomics (www.integratedgenomics.com) is a provider of bioinformatics products and services for the life sciences industry. The company's expertise in microbial genomics includes genome sequencing, comparative genomics and custom bioinformatics applications. IG has developed and distributes ERGO™, the most advanced and comprehensive bioinformatics suite for microbial genomics on the market. ERGO™ contains the largest available integration of microbial genome data, including genome-derived metabolic reconstructions representing over 6,300 networked metabolic and non-metabolic pathways.
KRIBB (www.kribb.re.kr/eng/) is the only government research institute dedicated to biotechnology research across a broad span of expertise, from basic studies for the fundamental understanding of life phenomena to applied studies such as new drug discovery, novel biomaterials, integrated biotechnology, and bioinformation. KRIBB will contribute to Korea's economic development and people's welfare and lives. We will make dreams become reality. We ask you to continue your special interest and your ardent support in us.
Vinayak Kapatral, Ph.D.
Vice President, Business Development
312-491-0846 x 326